Category Archives: ARVs

  1. From ‘What if’ to ‘What Now’: Implementing the New Prevention Technologies

    Via AIDSMap, by Gus Cairns. Two consecutive sessions at the sixth International AIDS Society conference in Rome yesterday were devoted, now we have convincing scientific data on the benefits of treatment as prevention and PrEP, to putting these new prevention methods into practice. “We have moved from ‘What if?’ to ‘What now?’” was the comment of Mitchell Read More >>

    ARV, ARVs, cure, Dr. Anthony Fauci, HIV/AIDS, HIV/AIDS policy, IAS, IAS 2011, new prevention technologies, Rome, Treatment as Prevention
  2. Investment in HIV Prevention Research

    A report released yesterday by HIV Vaccines and Microbicides Resource Tracking Working Group at the IAS conference in Rome “found that overall investment in HIV prevention R&D had actually increased, with the modest exception of a one percent decline in vaccine R&D. The report documented a total US$1.19 billion investment in research and development (R&D) for four key HIV prevention Read More >>

    antiretroviral therapy, ARV, ARVs, circumcision, drug development, HIV/AIDS, IAS 2011, Microbicides, PrEP, rectal microbicide, research, vaccine, vaginal microbicide
  3. IAS 2011: Day 2 Press Release

    OFFICIAL PRESS RELEASE – DAY 2 16.30 (CET), MONDAY JULY 18 Antiretroviral Treatment is HIV Prevention: The proof is here Leading researchers and international experts to discuss the policy and prevention implications of three groundbreaking trial results: the HPTN O52 study, the Centers for Disease Control and Prevention TDF2 study and the University of Washington Partners PrEP Read More >>

    antiretroviral therapy, ARV, ARVs, Dr. Anthony Fauci, HIV/AIDS, HIV/AIDS policy, IAS, IAS 2011, new prevention technologies, prevention, Rome, Treatment as Prevention
  4. Microbicide Trials Network Statement On The Partners PrEP Study And The CDC’s TDF2 Study: VOICE Study Will Continue

    Via Medical News Today. Researchers from two major HIV prevention trials announced favorable results of an approach called oral pre-exposure prophylaxis, or PrEP. One of these trials, the Partners PrEP Study, has provided the strongest evidence yet of PrEP’s effectiveness. Information from both studies will need to be fully evaluated before it can be determined what impact Read More >>

    ARV, ARVs, HIV, HIV transmission, Microbicides, new prevention technologies, PrEP, prevention, rectal microbicide, Tenofovir, Truvada, vaginal microbicide
  5. IAS 2011 HIV Prevention Research Roadmap

    Via our friends at AVAC. Where: Rome, Italy When: July 17 – July 20, 2011 The IAS Conference on HIV Pathogenesis, Treatment and Prevention is held every two years, and this year it will take place in Rome, July 17-20. The 2011 conference has a program that includes many sessions on a range of HIV-related topics. AVAC Read More >>

    ARV, ARVs, AVAC, HIV transmission, HIV/AIDS, IAS, IAS 2011, new prevention technologies, PrEP, Rome
  6. Project Inform Reports: Financing Recommendations for PrEP

    Project Inform recently released a report titled Financing and Delivery Mechanisms to Increase Pre-Exposure Prophylaxis (PrEP) Access in Populations at High-Risk of HIV Infection. Available here, the report discusses issues related to financing for PrEP to ensure that it becomes a viable, accessible prevention method for MSM. Here as an excerpt from the executive summary of the Read More >>

    ARV, ARVs, Gilead, HIV/AIDS, HIV/AIDS policy, HIV/AIDS. pre-exposure prophylaxis, PrEP, Truvada
  7. AIDS Summit at the UN: Not Enough Talk About Sex

    Via the Huffington Post, by Evelyn Leopold. World leaders gathered at the United Nations to mark the 30th anniversary of the HIV/AIDS epidemic and put out a 102-paragraph declaration. Adrienne Germain, the president of the International Women’s Health Coalition (IWHC), has been working on women’s issues all her adult life and was active in the 1994 Cairo Read More >>

    ARV, ARVs, family planning, HIV/AIDS, HIV/AIDS policy, MSM, sex work, United Nations
  8. Bloomberg Editorial: Treatment has Grown, Prevention Has Languished

    via Bloomberg AIDS has been with us, officially, for 30 years, since the U.S. Centers for Disease Control and Prevention reported the first cases. This unhappy anniversary is perhaps as good a time as any to spell out why the global response to AIDS is in need of serious adjustment. Annual spending on AIDS worldwide has risen Read More >>

    ART, ARVs, funding, HIV/AIDS policy, new prevention technologies, TLC+, Treatment
  9. NEWS ROUNDUP: Early HIV Treatment Can Reduce Transmission Risk By 96%, Study Results Show

    via Kaiser Family Foundation Results from a multicountry clinical trial, sponsored by the National Institute for Allergy and Infectious Diseases (NIAID), show that HIV-positive people who take combination antiretroviral therapy (ART) can reduce the risk of transmitting the virus to their HIV-negative partners by 96 percent, U.S. researchers announced on Thursday “[i]n what is being hailed as Read More >>

    ARV, ARVs, couples, heterosexual epidemic, HIV/AIDS policy, research, Treatment
  10. ARVs Dramatically Reduce Risk of Passing HIV to Healthy Partners

    via Health Behavior News Service, by Glenda Fauntleroy When one partner in a couple is infected with HIV and the other is not, treatment with antiretroviral drugs can dramatically lower the chances of the infected partner passing along the disease to his or her mate, a new evidence review finds. Patients with HIV receive a combination of Read More >>

    ARV, ARVs, couples, HIV/AIDS policy, Treatment